A Multicentre, Open, Non-comparative, Phase III Study on the Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 22.5 mg 6-month Formulation in Patients With Advanced Prostate Cancer
Phase of Trial: Phase III
Latest Information Update: 03 Feb 2016
At a glance
- Drugs Triptorelin (Primary)
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Sponsors Debiopharm Group
- 10 Jun 2017 Biomarkers information updated
- 31 Jan 2014 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 05 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.